Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-188-DOTA-cetuximab
- Development stage
- Unknown
- Lead developer
- Timothy Marr
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Rhenium-188-DOTA-cetuximab (188Re-DOTA-cetuximab) is an investigational radioimmunotherapy (radioimmunoconjugate) consisting of cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), conjugated via the macrocyclic chelator DOTA to the therapeutic beta-emitting radioisotope rhenium-188 (188Re). It is being investigated as a targeted radionuclide therapy for patients with advanced head and neck squamous cell carcinoma (HNSCC) who have exhausted standard surgical and radiotherapy options. In a theranostic approach (such as in the ReCHANCE study led by Dr. Timothy Marr), patients first undergo imaging with gallium-68-DOTA-cetuximab to assess EGFR-mediated tumor uptake; those with sufficient uptake can then proceed to salvage treatment with rhenium-188-DOTA-cetuximab or lutetium-177-DOTA-cetuximab to deliver localized cytotoxic radiation directly to the tumor cells.
- Other names
- rhenium-188-cetuximabrhenium188-cetuximabrhenium 188-cetuximab188Re-DOTA-cetuximab188Re-cetuximab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on rhenium-188-DOTA-cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-188-DOTA-cetuximab.